€25 per 1mg
€1.000 per 100mg
The IGFs are mitogenic, polypeptide growth factors that stimulate the proliferation and survival of various cell types, including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar to insulin by structure and function but have a much higher growth-promoting activity than insulin. IGF-I LR3 is a recombinant analog of human IGF-I comprised of the complete IGF-I sequence, with an Arginine substitution for the third position Glutamic acid, and a 13 amino acid length N terminus peptide extension. Specifically engineered for higher biological potency in vitro, IGF-I LR3 has an increased half-life and a binding aversion to native proteins within the body that make it ideal for both research and large-scale culturing.
Recombinant MESOkine IGF-1 LR3 is produced in the endosperm tissue of barley seed (Hordeum vulgare).
Tris pH 7.4, sterile filtered through 0.2 um filter.
IGF-1 LR3 is purified from barley seeds resulting in an extract containing purified recombinant IGF-1 LR3 protein along with co-purified barley seed proteins. The amount of the recombinant IGF-1 LR3 protein is typically in the range of 20-30% of total purified protein content. The exact content of the growth factor is stated on the vials. The co-purified barley seed proteins serve as stabilizing proteins that can prolong the lifetime of the recombinant protein and may enhance the bioactivity of growth factors in standardized bioassays.
Always centrifuge the vial before opening. It is recommended to reconstitute the lyophilized protein in sterile buffered saline or a solution of your choice, to a concentration of 50 µg/ml. The lyophilized protein, though stable at room temperature for few weeks, is best stored at -20°C. Reconstituted protein should be used immediately or stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles.
Each batch of MESOkine growth factor is tested for bioactivity and verified to have comparable activity to a commercial source. Bioactivity is assayed by measuring the dose dependent effect of recombinant human MESOkine IGF-I LR3 on proliferation of FDC-P1 cells, murine progenitor cells of granulocytes, monocytes and macrophages. The ED50 for this effect of using recombinant human MESOkine® IGF-I LR3 is typically below 0,1 ng/ml, corresponding to specific activity of > 10 x 10e6 U/mg. Optimal concentration should be determined for specific applications and cell lines.
MESOkine IGF-1 LR3, recombinant, human, is a non-glycosylated polypeptide chain containing 83 amino acid residues and a 14 a.a. Histidine-based tag for a total length of 97 a.a. with a predicted total molecular mass of 10.76 kDa. The recombinant protein migrates with an apparent molecular mass of 12.5 kDa in SDS-PAGE.